Cargando...
A longitudinal VBM study monitoring treatment with erythropoietin in patients with Friedreich ataxia
BACKGROUND: Recombinant human erythropoietin (rhuEPO) has received considerable attention because of its neuroprotective properties. It has recently been reported that rhuEPO increases frataxin levels in combination with clinical improvement in rhuEPO treated patients with Friedreich ataxia (FRDA)....
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
SAGE Publications
2014
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4184378/ https://ncbi.nlm.nih.gov/pubmed/25298866 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2047981614531573 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|